biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by chrispion Jun 16, 2022 8:48am

161 Views

Post# 34760700

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

This is fantastic news! :) https://www.globenewswire.com/news-release/2022/06/16/2463857/0/en/Bioasis-Acquires-Phase-2-Ready-Rare-Orphan-EGF-Assets.html

Finally people can't say "you aren't in the clinic (human dosing) with xB3" anymore.
It might not happen today (with the overall depressed market given the Fed's interest rate decision yesterday) but this opens investment in Bioasis to a new set of investors on both sides of the border.

Just the start of good things till the end of the year imo.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"